TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06760221

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body raiotherapy
Description: Neoadjuvant stereotactic body radiation therapy followed by radical surgery for soft tissue sarcoma.
Study: NCT06759324

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Live kombucha (non filtered/ non pasteurized)
Description: Participants receive a daily amount of 33 cl of live kombucha (non-pasteurized/ non-filtered) for 4 weeks (28 days).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasteurized kombucha (non filtered)
Description: Participants receive a daily amount of 33 cl of kombucha (pasteurized drink) for 4 weeks (28 days).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (sparkling water)
Description: Participants receive a daily amount of 33 cl of sparkling water for 4 weeks.
Study: NCT04908202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05549661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound imaging
Study: NCT06384729

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EXOPULSE Mollii Ⓡ
Description: The EXOPULSE Mollii method (EXONEURAL NETWORK AB, Danderyd, Sweden) is an innovative approach to non-invasive and self-administered electrical stimulation with multiple electrodes incorporated into a full-body suit. It consists of comfortable, breathable, and washable synthetic material pants and a jacket. It has been primarily designed to reduce disabling spasticity and improve motor function. The method refers to the concept of reciprocal inhibition induced by stimulating the antagonist of a spastic muscle, at low frequencies and intensities, which is considered to reduce spasticity.
Study: NCT06220071

Intervention type: OTHER
Intervention: Case series review of clinical and radiographic data
Description: Extraction of clinical and radiographic data related to patients' history from medical records
Study: NCT05310136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBTi
Description: On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi, sleep diaries, and adherence record. In the end of weeks 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
Study: NCT05278871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constructive Shearwave Interference (CSI)
Description: handheld ultrasound
Study: NCT05774951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: Camizestrant. Experimental. Administered orally
Study: NCT06384729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXOPULSE Mollii Ⓡ
Description: The EXOPULSE Mollii method (EXONEURAL NETWORK AB, Danderyd, Sweden) is an innovative approach to non-invasive and self-administered electrical stimulation with multiple electrodes incorporated into a full-body suit. It consists of comfortable, breathable, and washable synthetic material pants and a jacket. It has been primarily designed to reduce disabling spasticity and improve motor function. The method refers to the concept of reciprocal inhibition induced by stimulating the antagonist of a spastic muscle, at low frequencies and intensities, which is considered to reduce spasticity.
Study: NCT06293326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bi-layer calcium carbonate tablet (BAY1180654)
Description: Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
Study: NCT05774951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen. Comparator. Administered per local approved label

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole. Comparator. Administered per local approved label

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole. Comparator. Administered per local approved label

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane. Comparator. Administered per local approved label
Study: NCT04928248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Dashboard integrated with Disease Manager App
Description: The Diabetes Dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface. The Diabetes Dashboard is integrated within the diabetes module of the EHR-integrated Disease Manager App, which uses key information from the Diabetes Dashboard and provides a link to the Diabetes Dashboard.
Study: NCT06154239

Intervention type: DEVICE
Group type: OTHER
Intervention: DAYE Diagnostic Tampon
Description: The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746). The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion.

Intervention type: DEVICE
Group type: OTHER
Intervention: DAYE Diagnostic Tampon
Description: The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746). The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vaginal self-swab
Description: A vaginal self-swab typically consists of a long, slender, and flexible stick or handle, often made of plastic or a similar material. At one end, there's a soft, absorbent tip made of cotton or synthetic material. This tip is designed to collect a sample from the vaginal walls or cervix.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Vaginal self-swab
Description: A vaginal self-swab typically consists of a long, slender, and flexible stick or handle, often made of plastic or a similar material. At one end, there's a soft, absorbent tip made of cotton or synthetic material. This tip is designed to collect a sample from the vaginal walls or cervix.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clinician vaginal swab
Description: A clinician vaginal swab is a medical tool used by healthcare professionals to collect samples from the vaginal canal for diagnostic purposes. It's typically a long, thin, and flexible instrument. At one end, there's a cotton, rayon, or synthetic tip designed to collect cells, discharge, or other materials from the vaginal walls, cervix, or other areas within the vaginal canal.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clinician vaginal swab
Description: A clinician vaginal swab is a medical tool used by healthcare professionals to collect samples from the vaginal canal for diagnostic purposes. It's typically a long, thin, and flexible instrument. At one end, there's a cotton, rayon, or synthetic tip designed to collect cells, discharge, or other materials from the vaginal walls, cervix, or other areas within the vaginal canal.
Study: NCT05454163

Intervention type: OTHER
Intervention: SNOT 22 questionnaire
Description: 22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)
Study: NCT06142851

Intervention type: OTHER
Intervention: Data collection
Description: data collection
Study: NCT04874558

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultra-low dose chest CT
Description: A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.
Study: NCT05971563

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein
Description: Natural protein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-amino acids
Description: Synthetic amino acids based protein substitute for Phenylketonuria

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CGMP-AA
Description: Glycomacropeptide based protein substitute for Phenylketonuria
Study: NCT05844449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: Fixed-dose combination tablets for oral administration.
Study: NCT06552624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magaldrate
Description: A dose of T drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magaldrate
Description: A dose of T drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magaldrate
Description: A dose of R drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magaldrate
Description: A dose of R drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
Study: NCT04725305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiZact
Description: It has been described as describes a bipolar device that continuously measures impedance of clamped tissue, adjusting energy levels in real time and automatically stopping energy delivery when a seal is established. Their literature suggests the device permanently seals vessels up to 3mm with less thermal damage, resulting in less intraoperative blood loss, more efficient procedures, and possibly less pain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: This method would involve removal of tonsils using electrocautery technique
Study: NCT05167877

Intervention type: OTHER
Intervention: No intervention will be given to the participants
Description: This is an observational feasibility study with no intervention.

Intervention type: OTHER
Intervention: No intervention will be given to the participants
Description: This is an observational feasibility study with no intervention.
Study: NCT03768310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19.CAR-multiVST for Group A
Description: Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the transplant (between days 30 and 90). A time period of 6 weeks will constitute the time for clinical safety monitoring.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19.CAR-multiVST for Group B
Description: Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the bone marrow transplant. A time period of 6 weeks will constitute the time for clinical safety monitoring. If patients with relapse after transplant or those with evidence of disease before bone marrow transplant have at least a partial response to the treatment or have stable disease, they will be eligible to receive up to 6 additional doses of T cells separated by a minimum of four weeks. Patients are eligible to receive additional doses only after they have completed the initial 6-week clinical safety monitoring period.
Study: NCT04970979

Intervention type: OTHER
Intervention: survey
Description: questionnaire about the influencing factors of home-based cardiac rehabilitation
Study: NCT05528341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKG2D-CAR-NK92 cells
Description: NKG2D-CAR-NK92 cells will be administered intravenously over 1h. The starting dose of NKG2D-CAR-NK92 cells will be 0.5×10\^6-2×10\^6/kg, twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
Study: NCT06293326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bi-layer calcium carbonate tablet (BAY1180654)
Description: Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release calcium carbonate tablet (BAY1180654)
Description: Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release calcium carbonate tablet (BAY1180654)
Description: Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
Study: NCT05253222

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: retrograde image by colonic TET
Description: Delivery of contrast fluid by colonic TET Each participant will receive one delivery of 200 ml contrast fluid by colonic TET to the distal portion of the lesion.~One group will be taken CT investigation, another group will be taken X-ray fluoroscopy.~Imaging parameters will be collected and evaluated.
Study: NCT05915793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm strengthening and accessory muscles stretchings
Description: Diaphragm strengthening and accessory muscles stretchings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragm strengthening
Description: Diaphragm strengthening
Study: NCT04987255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free visit
Description: The persons with sedentary (healthy) in this group will have to visit the museum freely (without a guide) for a period of 75 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided visit
Description: The persons with sedentary (healthy) in this group will have to visit the museum with a guide for a period of 75 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Guided visit (stroke)
Description: The persons with motor disability after stroke in this group will have to visit the museum with a guide for a period of 75 minutes.
Study: NCT06085573

Intervention type: DRUG
Intervention: Dexmedetomidine Hydrochloride
Description: \<Sedation of non-invasive procedures and tests without intubation in pediatrics\> For children aged 2 years or older, the usual dosage of dexmedetomidine is 12 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~For children aged 1 month to \< 2 years old, the usual dosage of dexmedetomidine is 9 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~The infusion rate should be reduced according to patient's condition.
Study: NCT05109741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Psychodynamic Therapy
Description: Internet-based Psychodynamic Therapy based on the SUBGAP model developed by Farrell Silverberg

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based Behavioral Activation
Description: Internet-based Behavioral Activation based on the BATD-R model developed by Carl Lejuez and others.
Study: NCT05588453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given UD TGFbi NK cell IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT05817370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Training on screening and treatment of HSIL (e-STH)
Description: Tailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
Study: NCT06335654

Intervention type: DIAGNOSTIC_TEST
Intervention: artificial intelligence system
Description: The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. After endocytoscopic observation, the artificial intelligence system will be open and display the predictive result. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue. After endocytoscopic observation, the artificial intelligence system will be open again and display the predictive result.
Study: NCT05190419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orismilast modified release tablets
Description: Orismilast modified release is a next generation phosphodiesterase-4 (PDE4) inhibitor with high selectivity for the PDE4 subtypes linked to inflammation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orismilast modified release tablets
Description: Orismilast modified release is a next generation phosphodiesterase-4 (PDE4) inhibitor with high selectivity for the PDE4 subtypes linked to inflammation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orismilast modified release tablets
Description: Orismilast modified release is a next generation phosphodiesterase-4 (PDE4) inhibitor with high selectivity for the PDE4 subtypes linked to inflammation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT06513455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome（40mg/m2）
Description: irinotecan Liposome was administered 40mg/m2, D1，iv. q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel was administered 125mg/m2 D1、D8、D15，iv. q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel was administered 125mg/m2 D1、D8、D15，iv. q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine was administered 1000 mg D1、D8、D15，iv. q4w
Study: NCT05554471

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MYNX CONTROL™ Venous Vascular Closure Device 6F-12F
Description: Mynx Control Venous VCD 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MYNX CONTROL™ Venous Vascular Closure Device 6F-12F
Description: Mynx Control Venous VCD 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation.
Study: NCT06555237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib tablet
Description: Trametynib orally once daily in 0,025mg/kg dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Disopiramide and Beta blockers orally
Study: NCT04832919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Community-Family Partnership Intervention
Description: Nurses conduct home visits on a monthly basis for the first five months post-baseline. During visits, nurses emphasize the importance of infection control measures and, jointly with household members, develop and follow-up on the implementation of an infection control plan tailored to the unique circumstances of the household. Nurses deliver training on infection control skills necessary for optimal implementation of the plan. Nurses offer at-home SARS-CoV-2 testing to all members of the household. Nurses conduct triage, medical case management, monitoring, and follow-up of individuals identified to have COVID-19 or any other acute health emergencies. CHWs conduct visits on a bi-weekly basis for the first five months post-baseline. CHWs deliver healthcare information and medical mistrust counseling in a culturally relevant and linguistically appropriate fashion; and provide social support, navigate household members to social welfare/vocational/economic/psychosocial services.
Study: NCT05320692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE+Camrelizumab+Apatinib mesylate
Description: TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE Alone.
Study: NCT05072717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion with Indocyanine green
Description: Infusion of Indocyanine green to determine perfusion in meniscal tear tissue.
Study: NCT06365671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous stem-cell transplantation
Description: high-dose chemotherapy and autologous stem-cell transplantation (HDT/ASCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relmacabtagene autoleucel (relma-cel)
Description: relma-cel (CD19 CAR-T cell)infusion on day 3(±1d) after ASCT with a fixed dose of 100X10\^6.
Study: NCT06254027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forte
Description: One application per day for a complete treatment period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Cover Light
Description: One application per day for a complete treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loceryl
Description: One application per week for a complete treatment period.
Study: NCT06102252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel/epirubcin/carboplatin
Description: adjuvant treatment in endometrial carcinoma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel/carboplatin
Description: Dose dense paclitaxel/carboplatin
Study: NCT04142489

Intervention type: OTHER
Group type: OTHER
Intervention: solar irradiation and biopsies
Description: the minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage.